Compound, process to decrease iop, to improve blood flow to the end of the optic nerve and the retina, and to treat retinal diseases, compositions to decrease iop, to improve blood flow to the end of the optic nerve and the retina, and to treating retinal diseases, process and composition to provide neuroprotection to the end of the optic nerve or the retina, and, process to treat people suffering from sleep disorders, depression, schizophrenia, anxiety, circadian rhythmic disorders and centrally and peripherally mediated hypertension

摘要

"COMPOUND, PROCESSES TO REDUCE IOP, TO IMPROVE THE BLOOD FLOW FOR THE END OF THE OPTIC NERVE AND THE RETINA, AND TO TREAT RETINAL DISEASES, COMPOSITIONS TO REDUCE IOP, TO IMPROVE THE BLOOD FLOW AND THE EXTREME NON-BREAKING FLOW, AND THE EXTREME NORMAL AND FLOWING OF THE EXTREME NUT AND THE EXTREME NORMAL FLOW. TO TREAT RETINAL DISEASES, PROCESS AND COMPOSITION TO PROVIDE NEUROPROTECTION FOR THE END OF THE OPTICAL NERVE OR RETINA, AND, PROCESS TO TREAT PEOPLE SUFFERING FROM SLEEPING DISTURBANCES, DEPRESSION, SCHIZOPHRENIA, ANYTHERSYRTH, ANYTHERSYRTH, ANYTHHEROSIS, HISTORIC RISK, with affinity for 5HT ~ 7 ~ receptor (some of which are new) usable to decrease IOP, improve blood flow to the optic nerve end and retina, provide neuroprotection and treat retinal diseases. The compounds are also usable for the treatment of sleep disorders, depression, and other psychiatric disorders, such as schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythm disorders, and centrally and peripherally mediated hypertension. The compositions and processes for their use are also described.